KIT and acquired polycythemia vera: Recently reported data collected from deep targeted sequencing indicated that KIT D816 mutations can be identified in 1–6% of patients with various subtypes of myeloid neoplasms, e.g., MDS, MDS/MPN-u, CMML, polycythemia vera, essential thrombocythemia, or myelofibrosis [39–44].